Cargando…

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review

Chinese national guidelines recommend various systemic therapies for patients with advanced hepatocellular carcinoma (HCC), but optimal treatment selection remains uncertain. To summarize the evidence supporting the systemic treatment of Chinese patients with advanced HCC, we performed a systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lan, Sun, Junhui, Wang, Kui, Zhao, Haitao, Zhang, Xijie, Ren, Zhenggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600684/
https://www.ncbi.nlm.nih.gov/pubmed/36290852
http://dx.doi.org/10.3390/curroncol29100575
_version_ 1784816904232239104
author Zhang, Lan
Sun, Junhui
Wang, Kui
Zhao, Haitao
Zhang, Xijie
Ren, Zhenggang
author_facet Zhang, Lan
Sun, Junhui
Wang, Kui
Zhao, Haitao
Zhang, Xijie
Ren, Zhenggang
author_sort Zhang, Lan
collection PubMed
description Chinese national guidelines recommend various systemic therapies for patients with advanced hepatocellular carcinoma (HCC), but optimal treatment selection remains uncertain. To summarize the evidence supporting the systemic treatment of Chinese patients with advanced HCC, we performed a systematic review using a literature search of PubMed, Embase, China National Knowledge Infrastructure, and the Chinese Scientific Journal Database between 1 January 2009 and 15 June 2021, and abstracts from ASCO 2020, ASCO GI 2021, ESMO 2020, and ESMO GI 2020. The inclusion criteria were: Chinese patients aged ≥18 years with advanced HCC; first- or second-line systemic therapy; an evaluation of the efficacy or safety outcomes; and a randomized controlled, non-randomized controlled, prospective, or retrospective design. Thirty reports were identified for the following therapies: the single-agent tyrosine kinase inhibitor (TKI; n = 10), single-agent programmed death-1 (PD-1) inhibitor (n = 4), chemotherapy (n = 5), PD-1/programmed death-ligand 1 (PD-L1) inhibitor plus TKI (n = 6), PD-1/PD-L1 inhibitor plus bevacizumab or biosimilar (n = 4), and PD-1/PD-L1 inhibitor plus chemotherapy (n = 1). The heterogeneity between the studies precluded statistical analysis and the data were summarized using tables. In the first-line setting, evidence supported the use of atezolizumab or sintilimab plus bevacizumab or a biosimilar. There remains insufficient evidence to determine the optimal approved TKI-based therapeutic option, and active controlled trials in the second-line setting were lacking.
format Online
Article
Text
id pubmed-9600684
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96006842022-10-27 First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review Zhang, Lan Sun, Junhui Wang, Kui Zhao, Haitao Zhang, Xijie Ren, Zhenggang Curr Oncol Systematic Review Chinese national guidelines recommend various systemic therapies for patients with advanced hepatocellular carcinoma (HCC), but optimal treatment selection remains uncertain. To summarize the evidence supporting the systemic treatment of Chinese patients with advanced HCC, we performed a systematic review using a literature search of PubMed, Embase, China National Knowledge Infrastructure, and the Chinese Scientific Journal Database between 1 January 2009 and 15 June 2021, and abstracts from ASCO 2020, ASCO GI 2021, ESMO 2020, and ESMO GI 2020. The inclusion criteria were: Chinese patients aged ≥18 years with advanced HCC; first- or second-line systemic therapy; an evaluation of the efficacy or safety outcomes; and a randomized controlled, non-randomized controlled, prospective, or retrospective design. Thirty reports were identified for the following therapies: the single-agent tyrosine kinase inhibitor (TKI; n = 10), single-agent programmed death-1 (PD-1) inhibitor (n = 4), chemotherapy (n = 5), PD-1/programmed death-ligand 1 (PD-L1) inhibitor plus TKI (n = 6), PD-1/PD-L1 inhibitor plus bevacizumab or biosimilar (n = 4), and PD-1/PD-L1 inhibitor plus chemotherapy (n = 1). The heterogeneity between the studies precluded statistical analysis and the data were summarized using tables. In the first-line setting, evidence supported the use of atezolizumab or sintilimab plus bevacizumab or a biosimilar. There remains insufficient evidence to determine the optimal approved TKI-based therapeutic option, and active controlled trials in the second-line setting were lacking. MDPI 2022-09-30 /pmc/articles/PMC9600684/ /pubmed/36290852 http://dx.doi.org/10.3390/curroncol29100575 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Zhang, Lan
Sun, Junhui
Wang, Kui
Zhao, Haitao
Zhang, Xijie
Ren, Zhenggang
First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
title First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
title_full First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
title_fullStr First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
title_full_unstemmed First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
title_short First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
title_sort first- and second-line treatments for patients with advanced hepatocellular carcinoma in china: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600684/
https://www.ncbi.nlm.nih.gov/pubmed/36290852
http://dx.doi.org/10.3390/curroncol29100575
work_keys_str_mv AT zhanglan firstandsecondlinetreatmentsforpatientswithadvancedhepatocellularcarcinomainchinaasystematicreview
AT sunjunhui firstandsecondlinetreatmentsforpatientswithadvancedhepatocellularcarcinomainchinaasystematicreview
AT wangkui firstandsecondlinetreatmentsforpatientswithadvancedhepatocellularcarcinomainchinaasystematicreview
AT zhaohaitao firstandsecondlinetreatmentsforpatientswithadvancedhepatocellularcarcinomainchinaasystematicreview
AT zhangxijie firstandsecondlinetreatmentsforpatientswithadvancedhepatocellularcarcinomainchinaasystematicreview
AT renzhenggang firstandsecondlinetreatmentsforpatientswithadvancedhepatocellularcarcinomainchinaasystematicreview